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Abstract
Purpose Irosustat is a first-generation, orally active, irre-
versible steroid sulfatase inhibitor. We performed a mul-
ticentre, open label phase II trial of the addition of Irosustat
to a first-line aromatase inhibitor (AI) in patients with
advanced BC to evaluate the safety of the combination and
to test the hypothesis that the addition of Irosustat to AI
may further suppress estradiol levels and result in clinical
benefit.
Experimental design Postmenopausal women with ER-
positive locally advanced or metastatic breast cancer who
had derived clinical benefit from a first-line AI and who
subsequently progressed were enrolled. The first-line AI
was continued and Irosustat (40 mg orally daily) added.
The primary endpoint was clinical benefit rate (CBR).
Secondary endpoints included safety, tolerability, and
pharmacodynamic end points.
Results Twenty-seven women were recruited, four dis-
continued treatment without response assessment. Based
on local reporting, the CBR was 18.5% (95% CI
6.3–38.1%) on an intent to treat basis, increasing to 21.7%
(95% CI 7.4–43.7%) by per-protocol analysis. In those
patients that achieved clinical benefit (n = 5), the median
(interquartile range) duration was 9.4 months (8.1–11.3)
months. The median progression-free survival time was
2.7 months (95% CI 2.5–4.6) in both the ITT and per-
protocol analyses. The most frequently reported grade 3/4
toxicities were dry skin (28%), nausea (13%), fatigue
(13%), diarrhoea (8%), headache (7%), anorexia (7%) and
lethargy (7%).
Conclusions The addition of Irosustat to aromatase inhi-
bitor therapy resulted in clinical benefit with an accept-
able safety profile. The study met its pre-defined success
criterion by both local and central radiological assessments.
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material, which is available to authorized users.
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Introduction
Inhibition of the activity of the transcription factor
oestrogen receptor alpha (ER) represents a cornerstone
strategy in the management of ER-positive (ER?) breast
cancer (BC). Lowering of circulating estradiol levels
through the inhibition of peripheral aromatase enzyme
activity is one of the key endocrine manipulations used in
the management of postmenopausal BC [1, 2]. However,
the second major pathway for oestrogen biosynthesis,
steroid sulfatase (STS), is yet to be exploited
therapeutically.
STS is responsible for the hydrolysis of steroid sulfates
to their unconjugated, biologically active forms converting
estrone sulphate (E1S) and DHEAS to estrone and DHEA,
respectively. STS mRNA is expressed in the majority of
ER? breast tumours and is inversely associated with sur-
vival [3, 4]. Expression of STS protein has been reported in
74% of breast cancers and its expression is significantly
associated with larger tumour size, and with an increased
risk of recurrence and poorer overall survival [5]. Con-
versely, the expression of oestrogen sulfotransferase (EST),
which opposes the actions of STS, inversely correlates with
tumour size, lymph node status and is significantly asso-
ciated with a decreased risk of recurrence and improved
overall survival [5]. The importance of DHEAS as a pre-
cursor for androstenediol was shown by its ability to
stimulate the proliferation of breast cancer cells, which
could be blocked with an anti-oestrogen or STS inhibitor,
but not an AI [6]. Serum DHEAS levels have been shown
to be significantly elevated in women progressing on an AI
[7] suggesting that androstenediol production from
DHEAS may be a mechanism of AI resistance. This is
supported by data from a neoadjuvant study, which found
an increase in STS following exposure to an aromatase
inhibitor (AI) [8]. This could therefore represent a com-
pensatory and adaptive response to the blockade of aro-
matase and the subsequent depletion of intratumoral
oestrogen.
Irosustat (STX64) a tricyclic coumarin sulphamate is a
first-generation irreversible inhibitor of STS [9]. Two
phase I studies of Irosustat have been performed [10, 11].
In the first, 14 women who had progressed on two prior
lines of endocrine therapy (ET) were treated with either 5
or 20 mg doses of Irosustat [10]. STS activity as measured
in peripheral blood lymphocytes (PBLs) and within the
breast tumours was almost completely inhibited following
treatment with Irosustat. As predicted by its mechanism of
action, there was a significant suppression of serum
estrone, estradiol, androstenediol and DHEA [10]. Four
patients (all previously progressed on AI) had stable dis-
ease for 2.75–7 months. In the second study, performed
following reformulation, the optimal biological dose
(OBD) was found to be 40 mg daily based on the reduction
of STS activity in peripheral blood, changes in circulating
steroidogenic hormones and the lack of grade 3 toxicity in
the first 28 days [11]. No objective responses were seen,
and the median time to progression for the 40 mg group
was 10.1 [(3.0–72.3) weeks]. Disease stabilisation was seen
in three of thirteen patients at the 40 mg dose, all of whom
remained progression free for at least 24 weeks (range
27.1–72.3 weeks). An FDG-PET-scan sub-study carried
out in six patients at the 40 mg dose revealed that 50% of
patients displayed significant median decreases in stan-
dardised uptake mean value (SUVmean), and hyperme-
tabolic tissular volume (HT Volume) at Day 28 [11]. In
both studies, Irosustat was well tolerated with no bio-
chemical or haematologic toxicities [10, 11]. Based on the
safety profile of Irosustat from these initial phase I studies
and the known side effect profile of AIs, no safety issues
were expected with regard to combining Irosustat with an
AI. Therefore, a phase II combination study was
developed.
The IRIS study was designed to investigate the efficacy
and tolerability of Irosustat in postmenopausal women who
had progressed on a first-line aromatase inhibitor (AI) from
which they had derived clinical benefit. This study aimed
to test the hypothesis that the blockade of STS with Iro-
sustat on the background of continued aromatase inhibition
could result in clinical benefit. Safety and pharmacody-
namic endpoints were also assessed.
Materials and methods
Study design
The IRIS study (ClinicalTrials.gov identifier NCT0178
5992) was a multicentre, open label phase II trial per-
formed in nine academic medical centres in the United
Kingdom (full list in supplementary information). Ethical
approval was given by the NRES Committee London-
Riverside (an Independent Ethics Committee; reference
12/LO/0477), as well as being approved by the United
Kingdom Medicines and Healthcare Products Regulatory
Agency (EudraCT: 2011-005680-25). All patients provided
written informed consent.
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Eligibility
Women were eligible if they were postmenopausal, with
histologically confirmed ER-positive, HER-2 negative
inoperable locally advanced or metastatic breast cancer.
ER positivity was based on local laboratory assessment.
Patients had to have developed progressive disease during
first-line AI treatment for recurrent ER-positive breast
cancer. Furthermore, patients had to have derived clinical
benefit, defined as a documented objective response at any
point or disease stabilisation (SD) for at least 6 months,
from this first-line AI treatment. The disease had to be
measurable by CT/MRI scan according to RECIST v1.1.
(Full inclusion and exclusion criteria in supplementary
information).
Trial treatment
Irosustat was given orally at a dose of 40 mg daily in
addition to the first-line AI, which was continued beyond
progression. No other therapy was given in the intervening
time between progression on the AI and commencement of
Irosustat. Combined therapy was continued until disease
progression, death, the development of unacceptable toxic-
ities or the withdrawal of consent.
Trial assessments
Clinical assessments and toxicity reporting were performed
every month (28 days) for the first 6 months and 3 monthly
thereafter until disease progression, occurrence of unac-
ceptable toxicities or withdrawal from treatment. A safety
visit was performed 7 days after Irosustat was discontinued.
Tumour response was evaluated every 3 months according
to RECIST version 1.1. Adverse events (AEs) were graded
according to National Cancer Institute Common Terminol-
ogy Criteria (version 4.3), with relationship to study medi-
cation recorded, and coded using the Medical Dictionary for
Regulatory Activities (MedDRA version 14.0). Formalin-
fixed paraffin-embedded (FFPE) samples were requested of
the primary tumour and any recurrence or metastatic site that
had been biopsied prior to study entry. Blood samples were
collected and processed at baseline, every month and on
progression (see supplementary information).
Study endpoints
The primary endpoint was clinical benefit rate which was
defined as the proportion of patients with either complete
response (CR) or partial response (PR) at any scheduled
tumour assessment, or stable disease (SD) for at least
6 months. Secondary endpoints included progression-free
survival (PFS), defined as time from study enrolment to first
evidence of PD or death due to any cause, duration of clinical
benefit as defined by the number of days from start of study
drug to the first evidence of progressive disease (PD) or death
due to any cause; objective response rate defined by the pro-
portion of CR and PR. Safety and tolerability as assessed by
the collection of adverse events (AE) according to the Com-
mon Terminology Criteria for Adverse Events (NCI-CTCAE
v 4.03) and to measure alterations in circulating steroid hor-
mones and correlate these measures with clinical outcome.
Exploratory translational endpoints included the assessment
of the expression of steroidogenic enzymes, i.e. STS, aro-
matase, EST, 17bHSD1 and 17bHSD2. Central review of all
study imaging was undertaken by an independent radiologist.
Steroidogenic hormone profiling
Steroidogenic Hormone profiling was carried out by a
central laboratory, Quest Diagnostics (Nichols Institute,
San Juan Capistrano, CA, USA). Androstenedione, oes-
trone sulfate (E1S), dehydroepiandrosterone sulphate
(DHEAS), dehydroepiandrosterone (DHEA), androstene-
diol and testosterone were quantitated using a TSQ
Quantum Ultra (Thermo Fisher; San Jose, CA) triple
quadrupole tandem mass spectrometer. Estrone and estra-
diol were detected and quantitated in negative ionisation
mode using a triple quadrupole tandem mass spectrometer
with APCI source (TSQ Quantum Ultra, Thermo Fisher;
San Jose, CA). Further detailed methodology is provided in
the supplementary materials and methods.
Immunohistochemistry staining
Immunohistochemistry was performed for the expression
of four enzymes involved in oestrogen metabolism (aro-
matase, steroid sulfatase, oestrogen sulfotransferase, 17-
beta-Hydroxysteroid dehydrogenase type 1 and type 2);
detailed methodology is described in supplementary
materials and methods.
Immunostained slides were independently evaluated by
two of the authors (FG, HS) who are experienced in scoring
the four biomarkers concerned, both were blinded to
patients’ clinical outcomes. Marker’s expression was
evaluated by assigning scores for the approximate per-
centage of immunopositive cells (proportion score) and for
staining intensity, which were added together. The range of
proportion scores for aromatase was 0–3 as follows:
0 B 1%, 1 = 1–25%, 2 = 26–50% and 3 C 50%
immunopositive cells (Sasano et al. 2009). The range of
proportion score for STS, EST and 17BHSD was 0–2 as
follows: 0 = no stained tumour cells, 1 = 1–50%,
2 C 50% immunopositive cells (5). Relative staining
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intensity of immunopositive cells was classified as 0 = no
immunoreactivity, 1 = weak, 2 = moderate and
3 = strong immunoreactivity.
Statistical analysis
The study used a Simon’s minimax two-stage design to
provide 80% power with a one-sided type I error of 0.05 to
declare the treatment effective assuming a maximum
unacceptable CBR (p0) of 5% and a minimum accept-
able CBR (p1) of 20%. In the first stage, 13 patients were to
be evaluated, and if at least one patient achieved clinical
benefit, another 14 patients would be enrolled. If the clin-
ical benefit was seen in 4 out of 27 patients overall, the
treatment would be declared effective. For PFS, patients
were censored at the time of the last follow-up if they had
withdrawn or been lost to follow-up before progression or
death. PFS was estimated using the Kaplan–Meier method.
All 27 patients enrolled in the study and who received at
least one dose of drug, formed the Intent to treat popula-
tion, while the per-protocol group included all patients
except three patients who withdraw themselves and one
who was withdrawn by the local principal investigator
prior to the first tumour assessment at 3 months.
Results
Between February 2013 and March 2014 28 patients were
consented. One patient was found to be ineligible prior to
starting treatment. All 27 patients enrolled in the study
received at least one dose of drug, and formed the ITT
population. Four patients withdrew from the study before
the first tumour assessment (Fig. 1). The baseline clinico-
pathological details of patients are provided in Table 1.
Prior to recruitment, all 27 patients were receiving an AI as
first-line therapy with a median (IQR) duration of treatment
of 21.1 (13.3–37.6) months; 27% of patients had received
one course of chemotherapy for advanced disease.
Drug compliance was monitored using a patient diary. Of
the 27 patients in the study, drug compliance data were
available for 26 patients as one patientmislaid her drug diary.
The compliance with both AI treatment and Irosustat during
the study was very good with median rates of 100% (range
90.5–100%) and 100% (range 87.0–100%), respectively.
Efficacy
For the 27 patients recruited, the median duration of treat-
ment was 2.8 months (range 1.5–17.4 months). Based on the
local study sites’ tumour assessment, there were no objective
responses. At the interim analysis when the primary outcome
for the first 13 patients was available, we observed three
patients with clinical benefit (three stable diseases for at least
6 months) and the trial moved to the second stage, where
another two patients with clinical benefit were observed. In
summary, five patients had stable disease for at least
6 months giving a clinical benefit rate (CBR) of 18.5% (95%
CI 6.3–38.1%) on an intent to treat basis (Table 2). In a per-
protocol analysis which excluded the four patients who
withdrew before the first tumour assessment, the CBR was
21.7% (95% CI 7.4–43.7%).
Central review was undertaken for all patients where at
least one radiological assessment had been undertaken (i.e.
the per-protocol group) which confirmed that there were no
objective responses (Table 2). As a result of the central
review, four patients derived clinical benefit, giving a CBR
of 14.8% (95% CI 4.2–33.7%) based on intent to treat
analysis and 17.4% (95% CI 5.0–38.8%) in the per-proto-
col analysis.
The median (IQR) duration of clinical benefit in the
local ITT analysis of 26 patients was 9.4 months
(8.1–11.3); the precise date of starting study drug was
unknown for one patient. PFS based on local review was
2.7 months (95% CI 2.5–4.6) in both the ITT and the per-
protocol analysis (Fig. 2).
Adverse events
All twenty-seven patients experienced treatment-emergent
adverse events, 91% of which were grade 1 or 2 (Table 3).
The most common were dry skin (77%), nausea (48%) and
fatigue (40%). Grade 2 ECG abnormalities (QT prolonga-
tion) were reported in one patient, which were considered
unrelated to study drug. Three patients were discontinued
due to AEs; these were urinary tract infection, possible
renal toxicity (not reported as AE) and dry skin.
Nine serious adverse events occurred in 6 patients
(22%). None were considered definitely related to study
drug; one was considered probably related (nausea and
vomiting) and another possibly related (nausea and vom-
iting). All other SAEs were considered as either unlikely to
be related (sepsis, urinary tract infection, breast pain) or not
related (cellulitis secondary to an animal bite, symptoms of
morphine toxicity, pneumonia). There was one death due to
bronchopneumonia during the study that was unrelated to
the study medication.
Pharmacodynamic data
At study entry and at all subsequent monthly time points,
the circulating levels of estradiol and estrone were below
the threshold of detection in all patients (2 and 10 ng/dl,
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respectively, data not show). There were significant
decreases in androstenedione, DHEA (p\ 0.01) and
testosterone (p = 0.03), as well as significant increases in
DHEAS (p = 0.02) and DHEA:DHEAS ratio (p\ 0.01) at
3 months (Table 4). At 6 months with fewer samples,
available statistical significance was lost.
Immunohistochemistry data
STS, EST, Aromatase, 17BHSD1 and 17BHSD2
immunostaining was successfully performed on the pri-
mary tumours from 19 patients, a biopsy of the first relapse
in three cases and on AI progression in one cases and
includes three who derived clinical benefit from Irosustat.
(Supplementary Table 1 and representative micrographs of
staining in supplementary Fig. 1). Of note, only 37% (7 of
19) and 25% (1 of 4) of primary and recurrent samples had
moderate to strong (score C4) positivity for STS.
Discussion
IRIS is the first study to explore the efficacy of the sulfatase
inhibitor Irosustat in ER-positive metastatic breast cancer
in combination with an AI. In this study, we added steroid
sulfatase inhibition to the background aromatase inhibition
upon which disease progression had occurred. The under-
lying rationale for the study is based on multiple obser-
vations. Firstly, that after estrone is synthesised from
androstenedione (Adione), much of it is rapidly sulphated
to estrone sulfate (E1S), by the enzyme oestrogen sulfo-
transferase (EST) [12]. E1S is known to have a plasma
concentration 10–20 times higher than those of the
unconjugated oestrogens estrone and estradiol, as well as a
longer half-life in the plasma than the unconjugated
oestrogens and therefore acts as a reservoir for active
estrogens [13]. E1S uptake into malignant breast tissue is
facilitated by organic anion transporter polypeptide B
(OATP) [14]. Secondly, androgens derived from the
adrenal cortex are known to have oestrogenic effects [15].
Thirdly, STS, the enzyme responsible for the hydrolysis of
steroid sulphates to their unconjugated biologically active
forms, is overexpressed in breast cancer and is known to be
associated with a worse outcome [4, 5]. Fourthly, STS is
upregulated following exposure to an aromatase inhibitor
(AI) which is a putative mechanism of resistance to AIs [8].
Fifthly, the additive use of oestrogen synthesis inhibition
can result in clinical benefit as seen when an AI is added to
ovarian suppression in premenopausal women with breast
cancer [16]. We therefore hypothesised that the addition of
an STS inhibitor to an AI at disease progression would
result in a lowering of peripheral and intratumoral estrone
and DHEA, reversal of resistance and clinical benefit.
The principal findings relate to effect on disease status,
adverse events and effects on steroid hormones. Firstly,
regarding the anti-tumour effects of Irosustat, the study met
its primary endpoint of showing evidence of clinical benefit
in a second-line setting based on both local and central
reviews, with a median PFS of 2.7 months. Although there
Approached for 
participation
N=33
Declined
N=6 
Consented and 
Screened
N=28
Screen Failures
N=1
Enrolled (ITT)
N=27
Prolonged QT 
N=1
Completed (per-
protocol analysis set)
N=23
Withdrawn
N=4
Patient Decision N=3
PI Decision N=1
Fig. 1 CONSORT trial
diagram. ITT intent to treat, PI
principal investigator
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Table 1 Clinicopathological details
ITT N = 27 Per-protocol analysis N = 23
Age (years) 63.7 (10.5) 63.3 (9.9)
BMI (kg/m2) 28.1 (6.3) 28.2 (6.6)
Duration of the AI treatment at enrolment (month)a 21.1 (13.3–37.6) 21.1 (10.3–35.7)
Time between primary diagnosis to metastatic diagnosis (month)a 60.7 (2.0–116.1) [n = 23] 60.7 (2.0–105.4) [n = 19]
Ethnicity
White 24 (88.9%) 21 (91.3%)
Asian 1 (3.7%) 1 (4.4%)
Black 1 (3.7%) 0 (0%)
Chinese 1 (3.7%) 1 (4.4%)
No. of sites of disease
1 7 (25.9%) 6 (26.1%)
2 9 (33.3%) 8 (34.8%)
3 7 (25.9%) 7 (30.4%)
4 1 (3.7%) 0 (0%)
5 2 (7.4%) 1 (4.4%)
Missing 1 (3.7%) 1 (4.4%)
Visceral disease
No 6 (22.2%) 6 (26.1%)
Yes 20 (74.1%) 16 (69.6%)
Missing 1 (3.7%) 1 (4.4%)
ER statusb
Positive 27 (100%) 23 (100%)
Negative 0 (0%) 0(0%)
PgR statusb
Positive 20 (74.1%) 16 (69.6%)
Negative 4 (14.8%) 4 (17.4%)
Unknown 3 (11.1%) 3 (13.0%)
HER2 statusb
0 10 (37.0%) 10 (43.5%)
1? 10 (37.0%) 7 (30.4%)
2? 3 (11.1%) 2 (8.7%)
Amplified 0 (0%) 0 (0%)
3?c 1 (3.7%) 1 (4.4%)
Not done 3 (11.1%) 3 (13.0%)
Treatment history: chemotherapy
No 10 (37.0%) 9 (39.1%)
Yes 17 (63.0%) 14 (60.9%)
Neoadjuvant 2 (9.1%) 1 (5.9%)
Adjuvant 14 (63.6%) 11 (64.7%)
Advanced 1st line 6 (27.3%) 5 (29.4%)
Treatment history: radiotherapy
No 13 (48.1%) 11 (47.8%)
Yes 14 (51.9%) 12 (52.2%)
Adjuvant 19 (63.3%) 18 (66.7%)
Palliative 11 (36.7%) 9 (33.3%)
Treatment history: endocrine therapy
No 0 (0%) 0 (0%)
Yes 27 (100.0%) 23 (100.0%)
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were no objective responses, a number of patients experi-
enced disease stabilisation for at least 6 months. It is
known that the objective response and clinical benefit rates
of second-line endocrine treatment are limited. For exam-
ple, the objective response rate to second-line endocrine
therapy in large phase III studies with exemestane or high-
dose fulvestrant has been reported to be in the range of
0.4–6.3%, while median PFS in these studies ranged from
2.8 to 3.8 months [17–19]. Therefore, Irosustat as a single
agent added onto the background of an AI has evidence of
clinical activity and, with the caveats relating to cross trial
comparison and their limitations, does show efficacy which
is comparable to both exemestane and high-dose fulves-
trant in this setting. Future studies need to explore the
clinical activity of dual aromatase and STS blockade as
first-line metastatic treatment in a patients likely to be
endocrine sensitive, as well selecting for STS expression.
The suppression of circulating estradiol is a key thera-
peutic strategy in the management of ER-positive breast
cancer, and all the women who entered this study had
estrone and estradiol levels below the level of detection as
the result of AI treatment. However, steroidogenic hor-
mones derived from the adrenal gland have been impli-
cated in AI resistance. DHEAS is the most abundant steroid
in the human circulation and has been shown to be sig-
nificantly elevated in women whose disease failed to
respond to an AI in the metastatic setting [7]. DHEA has
been shown to stimulate the proliferation of the oestrogen-
dependent MCF-7 human breast cancer cell line, as well as
a derived oestrogen-independent variant, and to transacti-
vate ER in both lines [20]. In vitro DHEAS has been shown
to transactivate both ER and the AR in a dose-dependent
manner, with the DHEAS induced AR transactivity abol-
ished by Irosustat [21]. DHEA can itself be converted to
androstenediol by 17b-HSD1, as well as to androstene-
dione via 3b-HSD1 and 17b-HSD2. Androstenediol is
known to have potent oestrogenic effects [15], and can
stimulate the growth of hormone-dependent breast cancer
cells both in vitro and in vivo [22, 23]. Androstenedione
has been demonstrated to induce recruitment of ER and
SRC3 to gene promoters and drive ER transcription [24]
and AI resistance in vitro [25]. Androstenedione was sig-
nificantly elevated in women on a second-line AI for
metastatic breast cancer as compared to women being
treated in the adjuvant setting [26]. Furthermore,
androstenedione can be converted to 5a-androstane-3b,
17b–diol (3bAdiol) which is itself estrogenic, and can
induce growth in breast cancer cells [27]. This compound
has also been implicated in endocrine resistance [28].
Clinically, previous studies have also shown that AIs do
not affect the levels of androstenediol [29], while serum
DHEAS was significantly higher in women who progressed
on an AI [7]. Steroids with potent estrogenic properties
may provide an escape mechanism for growth within a low
estradiol milieu.
Steroidogenic hormone measurements within the current
study revealed treatment with Irosustat resulted in signifi-
cant and predicable rise at 3 months in estrone sulphate and
DHEAS, and decrease in DHEA:DHEAS as well as sig-
nificant reduction in androstenedione at 3 months. These
pharmacodynamics data confirm that Irosustat had effected
sulfatase inhibition in our patients. Expression of STS and
Table 1 continued
ITT N = 27 Per-protocol analysis N = 23
Neoadjuvant
Anastrozole 1 (2.1%) 1 (2.5%)
Adjuvant
Exemestane 1 (2.1%) 1 (2.5%)
Letrozole 1 (2.1%) 1 (2.5%)
Anastrozole 4 (8.5%) 3 (7.5%)
Tamoxifen 16 (34.0%) 13 (32.5%)
Advanced 1st line
Exemestane 3 (6.4%) 3 (7.5%)
Letrozole 17 (36.2%) 14 (35.0%)
Anastrozole 4 (8.5%) 4 (10.0%)
ITT intent to treat
Data presented are mean (SD) for continuous variables and frequency (percentage) for categorical variables
a Data presented are median (inter quartile range)
b Based on diagnostic biopsy and primary tumour sample
c HER2 results: 3? on diagnostic biopsy and 1? on resected tumour
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other enzymes involved in oestrogen biosynthesis were
assessed predominately in primary breast cancer samples.
Given the small numbers, no formal assessment can be
made of the possible use of STS as a biomarker of
response. However, moderate to strong expression of STS
was observed in only 37 and 25% of the primary and
recurrent cases, and the preponderance of tumours with low
STS expression clearly may have impacted on the efficacy
data. Furthermore, the primary tissue was mainly used and
this may not reflect the biology of a tumour which has
progressed following a prolonged period of oestrogen
deprivation. Ideally, in future studies of Irosustat a meta-
static biopsy should be mandated prior to study entry [30],
and prospectively enrich for a STS high population of
tumours.
Irosustat was well tolerated with most adverse effects
being grades 1 and 2, and the most common being dry skin,
nausea and fatigue. Dry skin is an expected side effect
being reported in both phase I studies [10, 11]. This is
expected given that hereditary deficiency of STS results in
dry, scaly skin as a result of abnormal corneocyte retention
and thickening of the stratum corneum [31].
There are several limitations to our study. Primary
tumours were utilised for the IHC assessment since meta-
static biopsies from the time of study entry were not rou-
tinely collected [30], particularly given the evidence that
STS is upregulated following exposure to an AI [8]. Since
the study was initiated, the development of ESR1
Table 2 Efficacy analysis on the basis of local and central
assessment
ITT [n = 27] Per protocol [n = 23]
Local assessment
Clinical benefit rate 18.5% (6.3–38.1%) 21.7% (7.4–43.7%)
Response at 6 month scan
Complete response 0 0
Partial response 0 0
Stable disease 5 5
Progressive disease 16 16
Dead 1 1
Withdrawal 5 1
Central assessment
Clinical benefit rate 14.8% (4.2–33.7%) 17.4% (5.0–38.8%)
Response at 6 month scan
Complete response 0 0
Partial response 0 0
Stable disease 4 4
Progressive disease 15 15
Dead 1 1
Withdrawala 7 3
ITT intent to treat; Prior to 3 month scan: three patients decided to
withdraw; one patient withdrawn by local investigator. These four
patients had no scan and were excluded in the per-protocol analysis;
Between 3 and 6 month scan: one patient withdrawn
a At month 3: two patients PD reclassified as SD by central review
and thus treated as withdrawals
Fig. 2 Progression-free survival as assessed by the investigators in
the intention-to-treat population
Table 3 Treatment-emergent adverse events regardless of relation-
ship to study drugs
Adverse event Grade 1–2 Grade 3–4 Grade 5
Dry skin 21 1
Nausea 13 2
Fatigue 11 2
Diarrhoea 8 0
Decreased appetite 5 0
Headache 5 0
Lethargy 5 0
Vomiting 4 0
Rash 3 1
Cough 3 0
Dizziness 3 1
Arthralgia 3 0
Insomnia 3 0
Sepsis 0 1
Haemoglobin 0 1
Urinary tract infection 0 1
Breast ulceration 0 1
Gamma GT increase 0 2
Blurred vision 0 1
Bone pain 0 1
Pleurodesis 0 1
Pneumonia 0 0 1
Grades 1 and 2 with an incidence of 10% of study population and all
grade 3–5 toxicities
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mutations as a resistance mechanism to AIs has been
described. As all patients who entered the study had pro-
gressed on an AI, it would be expected that 20–30% would
harbour ESR1 mutations [32–34]. The possible effect of
ESR1 mutations with regard to the efficacy of Irosustat is
unknown. The study strengths are that we undertook local
and central review of radiology, with the study meeting its
primary endpoint by both assessments.
More recently, it has been demonstrated that the addi-
tion of either an mTOR inhibitor or a CDK4/6 inhibitor to
an AI can significantly improve the outcomes of women
with ER-positive metastatic breast cancer [17, 35]. Given
the clinical activity of these targeted therapies is dependent
on the dual targeting of ER with endocrine therapy, the
development of a more effective ET backbone may lead to
enhance efficacy of these biological therapies. Therefore,
any future clinical development will need to attempt to
address the question of whether an ET backbone which
comprises it and an AI is more clinically effective than an
AI alone when combined with targeted therapies such an
mTOR or CDK4/6 inhibitors.
In summary, this proof of concept study provides evi-
dence for the first time that combining both an AI and a
STS inhibitor can have clinical activity and that the com-
bination is safe and well tolerated. Future studies should
explore the clinical activity of Irosustat at an early line of
treatment in a populations enriched for STS expression.
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